The Capital Fund: Venture Capital (VC) investment for SMEs in Greater London, UK

Provides advanced technology-enabled solutions for digital dictation, medical transcription and speech recognition, primarily to UK hospitals.

Developing a pipeline of pre-clinical drugs and targets and providing its unique structural biology and chemistry services to major pharmaceutical and biotechnology firms.

Provides patient care messaging and health promotion solutions to the NHS, using mobile phones.

Using proprietary patented technology and knowhow, provides the pharmaceutical industry with end to end medical imaging services for clinical trials, from protocol.

Developer of bio-glass powders for dental applications such as whitening, desensitising or cutting teeth.

Development of stem cell technologies for drug discovery and regenerative medicine.

Works with the pharmaceutical industry to apply its patented site-specific PEGylation technology (TheraPEG) to optimise therapeutic molecules for the treatment and cure of important diseases, improving half-life without compromising biological activity.

Develops stem cell technologies to discover drugs that regenerate tissues of the human body.

The development and manufacture of a diagnostic instrument for the point of care measurement of HbA1C. This measurement is used in the monitoring of diabetics.

In October 2010, Quotient was acquired by AIM-listed EKF PLC.

Expanding chain of private health clinics, currently located in London, Coventry and Nijmegen, which offers an integrated approach to back pain management and works with major private medical insurers / case managers on specific programmes.

A world leader in the field of real time 3D surface imaging technology and equipment for use in radiotherapy treatment.